secwatch.observer — SEC 8-K summary
======================================

Issuer:     BridgeBio Oncology Therapeutics, Inc. (BBOT)
CIK:        0001869105
Form:       8-K
Filed at:   2025-02-10T23:59:59+00:00
Accession:  0001213900-25-011454
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Helix Acquisition Corp. II appoints Albert A. Holman, III to its Board of Directors
--------------------------------------------------------------------------------

- Albert A. Holman, III appointed on Feb 8, 2025 as Class III independent director.
- Holman brings life sciences investment banking experience; will serve on Audit Committee.
- Sponsor transferred 30,000 Class B ordinary shares to Holman in connection with appointment.
- Holman executed standard SPAC Letter Agreement and Joinder to Registration Rights Agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1869105/000121390025011454/0001213900-25-011454-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1869105/000121390025011454/ea0230467-8k_helixacq2.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-011454

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer